No, this is completely false—transdermal hormones absolutely show up in the blood.
Both transdermal estrogen and testosterone are specifically designed to be absorbed through the skin and produce measurable, therapeutic serum hormone levels. This is not only their intended mechanism of action, but monitoring these blood levels is a standard part of clinical care.
Evidence from FDA-Approved Products
The FDA labeling for testosterone gel explicitly states that transdermal application "delivers physiologic amounts of testosterone, producing circulating testosterone concentrations that approximate normal levels (300-1000 ng/dL)" 1. The pharmacokinetic data shows:
- Testosterone rises rapidly into the normal adult male range within hours of first application
- Steady-state serum levels are achieved within 48-72 hours
- About 9-14% of applied testosterone becomes bioavailable systemically
- When treatment stops, serum concentrations return to baseline within 48-72 hours 1
Clinical Monitoring Requirements
Both major endocrine society guidelines mandate routine blood monitoring specifically because transdermal hormones produce measurable serum levels:
For Testosterone Therapy
The Endocrine Society requires monitoring serum testosterone concentrations at specific intervals 2:
- Transdermal gels: Assess testosterone 2-8 hours after application, after at least 1 week of treatment
- Transdermal patches: Assess testosterone 3-12 hours after application
- Target is to achieve mid-normal range serum concentrations
For Estrogen Therapy
The Endocrine Society guidelines note that "clinicians usually do not measure estradiol levels to monitor therapy except when symptoms do not improve with escalating doses, particularly after changing the mode of administration from oral to transdermal" 3. This statement confirms that transdermal estrogen produces measurable blood levels—monitoring is simply not always necessary for symptom management.
Research Evidence Confirms Systemic Absorption
Multiple pharmacokinetic studies demonstrate measurable serum levels:
- Testosterone gel studies show serum testosterone levels increase 4-5 fold above baseline and remain stable throughout treatment, with steady-state achieved by day 2 4, 5
- Estrogen patch studies show estradiol concentrations increase from postmenopausal levels (<5 pg/mL) to 26-66 pg/mL depending on patch strength, with proportional dose-response 6
- Variability exists: The same transdermal estrogen dose can produce estradiol values differing by as much as 138 pg/mL between patients, confirming systemic absorption with individual variation 7
Transfer Risk Proves Systemic Absorption
The FDA documents that testosterone can transfer to others through skin contact, causing measurable blood level increases in untreated individuals 1:
- Direct skin-to-skin contact increased female partners' testosterone by 280% (Cavg) and 267% (Cmax)
- Even with a t-shirt covering the application site, increases of 6-11% occurred
This transfer risk would be impossible if transdermal hormones didn't enter the bloodstream.
Clinical Bottom Line
The entire premise of transdermal hormone therapy is systemic absorption. These formulations are engineered to bypass first-pass hepatic metabolism while delivering consistent serum hormone concentrations 3, 8. The claim that they "don't show up in blood" contradicts:
- FDA pharmacokinetic data
- Clinical practice guidelines requiring blood monitoring
- Decades of research demonstrating measurable serum levels
- Safety warnings about hormone transfer to others
Anyone suggesting transdermal hormones don't produce measurable blood levels is fundamentally misunderstanding how these medications work.